ArticleBMC cancer2025
Proton beam radiation therapy and the overall survival of adult and pediatric patients diagnosed with central nervous system tumors.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is an increased interest in using proton beam radiation therapy (PBT) in Central nervous system (CNS) tumors. However, no clear information exists about the association of PBT with the overall survival (OS) of patients diagnosed with CNS tumors. The current study aims to investigate the association of PBT with the OS of patients with CNS tumors.
methodsThis study included patients from the National Cancer Database diagnosed with CNS tumors between 2004 and 2022. Multivariable Cox regression analysis was used to assess the OS. The multivariable analyses were adjusted for age at diagnosis, sex, race, RT dose, health insurance, histology, education, income, comorbidity score, surgery, chemotherapy, and year of diagnosis.
resultsOf the 162,506 patients, 5,548 (3.4%) received PBT. In the multivariable Cox regression analysis, patients who received PBT had longer OS compared to patients who received photon RT (Hazard Ratio (HR): 0.67 [95% CI: 0.64-0.71], p < 0.001). In the subset analyses stratified by surgery, the use of PBT was associated with improved OS compared to photon RT in patients who received surgery (HR:0.76 [95% CI: 0.70-0.82], p < 0.001) and in patients who did not receive surgery (HR: 0.61 [95% CI: 0.57-0.65], p < 0.001). When stratified by histology, PBT was associated with improved OS compared to photon RT in patients diagnosed with astrocytoma (HR: O.65 [95% CI: 0.53-0.81], p < 0.001), glioblastoma (HR: 0.79 [95% CI: 0.71-0.88], p < 0.001) or other types (HR: 0.60 [95% CI: 0.37-0.98], p = 0.04) among patients who received surgery. PBT was also associated with improved OS compared to photon RT in patients diagnosed with astrocytoma (HR: O.44 [95% CI: 0.39-0.50], p < 0.001), glioblastoma (HR: 0.81 [95% CI: 0.73-0.90], p < 0.001) or other types (HR: 0.41 [95% CI: 0.28-0.60], p < 0.001) among those who did not receive surgery.
conclusionsPatients who received PBT had longer OS compared to patients who received photon RT (HR:0.67 [95% CI: 0.64-0.71], p < 0.001). In the subset analyses stratified by surgery, the use of PBT was associated with improved OS compared to photon RT in patients who received surgery (HR:0.76 [95% CI: 0.70-0.82], p < 0.001) and in patients who did not receive surgery (HR: 0.61 [95% CI: 0.57-0.65], p < 0.001).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.